[Study of the effects of vinpocetin on cognitive functions] - PubMed (original) (raw)
Clinical Trial
. 2012 Mar 30;65(3-4):115-20.
[Article in Hungarian]
Affiliations
- PMID: 23136730
Clinical Trial
[Study of the effects of vinpocetin on cognitive functions]
[Article in Hungarian]
Attila Valikovics et al. Ideggyogy Sz. 2012.
Abstract
Introduction: Chronic cerebral hypoperfusion is a risk factor for the development of certain types of dementia. Mild cognitive impairment is a stage of predementia condition, because the symptoms are similar but not as severe as the symptoms in patients with dementia. Vinpocetine, due to its complex mechanism of action, has an important role in the improvement of chronic cerebral hypoperfusion.
Objectives: The aim of our study was to determine the severity of the cognitive decline and to investigate the efficacy and safety of per os 18 months vinpocetine treatment in patients with mild cognitive impairment.
Methods: We used psychometrical tests (MMSE, ADAS-Cog) to assess the cognitive functions. CGIC-PGIC was used to evaluate the overall change in the disease status. ADL was used to assess the patient's daily activity and the Hamilton Depression Scale to evaluate the patient's mood. The assessments were performed at six visits during the 18 months treatment period.
Results: At the beginning of the treatment, the stage of our patients' mild cognitive impairment was moderately severe. Significant improvement was detected in the psychometrical tests after the 18 months treatment period. The overall status of the disease improved significantly according both to the patient and the investigator. Also significant improvement was detected in daily activity. The complex improvement of the clinical symptoms affected the patients' mood positively. Moreover, vinpocetine was safe and had a good tolerability during the whole study period.
Conclusions: Vinpocetine, due its complex mechanism of action, improved significantly the cognitive functions, overall disease status and quality of life in patients with chronic cerebral hypoperfusion. As a result, vinpocetine treatment can be recommended for patients with mild cognitive impairment.
Similar articles
- [Investigation of the effect of vinpocetine on cerebral blood flow and cognitive functions].
Valikovics A. Valikovics A. Ideggyogy Sz. 2007 Jul 30;60(7-8):301-10. Ideggyogy Sz. 2007. PMID: 17713111 Clinical Trial. Hungarian. - [The use of vinpocetine in chronic disorders caused by cerebral hypoperfusion].
Horváth S. Horváth S. Orv Hetil. 2001 Feb 25;142(8):383-9. Orv Hetil. 2001. PMID: 11263076 Review. Hungarian. - [The role of vinpocetine in the treatment of cerebrovascular diseases based in human studies].
Bagoly E, Fehér G, Szapáry L. Bagoly E, et al. Orv Hetil. 2007 Jul 22;148(29):1353-8. doi: 10.1556/OH.2007.28115. Orv Hetil. 2007. PMID: 17631470 Hungarian. - [Vinpocetin in neurological diseases].
Szapáry L, Késmárky G, Tóth K, Misnyovszky M, Tóth T, Balogh A, Nagy K, Németh GY, Fehér G. Szapáry L, et al. Ideggyogy Sz. 2012 Nov 30;65(11-12):387-93. Ideggyogy Sz. 2012. PMID: 23289173 Review. Hungarian.
Cited by
- New insights on the potential effect of vinpocetine in Parkinson's disease: one of the neglected warden and baffling topics.
Al-Kuraishy HM, Alexiou A, Papadakis M, Elhussieny O, Saad HM, Batiha GE. Al-Kuraishy HM, et al. Metab Brain Dis. 2023 Aug;38(6):1831-1840. doi: 10.1007/s11011-023-01254-y. Epub 2023 Jun 19. Metab Brain Dis. 2023. PMID: 37335452 Free PMC article. Review. - Memory Enhancers for Alzheimer's Dementia: Focus on cGMP.
Fedele E, Ricciarelli R. Fedele E, et al. Pharmaceuticals (Basel). 2021 Jan 13;14(1):61. doi: 10.3390/ph14010061. Pharmaceuticals (Basel). 2021. PMID: 33451088 Free PMC article. Review. - Phosphodiesterase Inhibitors for Alzheimer's Disease: A Systematic Review of Clinical Trials and Epidemiology with a Mechanistic Rationale.
Sanders O, Rajagopal L. Sanders O, et al. J Alzheimers Dis Rep. 2020 Jun 16;4(1):185-215. doi: 10.3233/ADR-200191. J Alzheimers Dis Rep. 2020. PMID: 32715279 Free PMC article. Review. - Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain.
Kelly MP. Kelly MP. Cell Signal. 2018 Jan;42:281-291. doi: 10.1016/j.cellsig.2017.11.004. Epub 2017 Nov 23. Cell Signal. 2018. PMID: 29175000 Free PMC article. Review. - The Relieving Effects of BrainPower Advanced, a Dietary Supplement, in Older Adults with Subjective Memory Complaints: A Randomized, Double-Blind, Placebo-Controlled Trial.
Zhu J, Shi R, Chen S, Dai L, Shen T, Feng Y, Gu P, Shariff M, Nguyen T, Ye Y, Rao J, Xing G. Zhu J, et al. Evid Based Complement Alternat Med. 2016;2016:7898093. doi: 10.1155/2016/7898093. Epub 2016 Apr 11. Evid Based Complement Alternat Med. 2016. PMID: 27190539 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials